Facebook Pixel Union Budget Drives Home.'VIKSIT BHARAT' MANTRA | Bio Spectrum - business - Bu hikayeyi Magzter.com'da okuyun
Magzter GOLD ile Sınırsız Olun

Magzter GOLD ile Sınırsız Olun

Sadece 9.000'den fazla dergi, gazete ve Premium hikayeye sınırsız erişim elde edin

$149.99
 
$74.99/Yıl

Denemek ALTIN - Özgür

Union Budget Drives Home.'VIKSIT BHARAT' MANTRA

Bio Spectrum

|

August 2024

Presenting the Union Budget for the seventh time in a row on July 23, the Union Minister for Finance and Corporate Affairs, Nirmala Sitharaman proposed to abolish 'angel tax' for all classes of investors and announced several measures like operationalisation of the Anusandhan National Research Foundation (ANRF) for basic research and prototype development and setting up a mechanism for spurring private sector-driven research and innovation at commercial scale with a financing pool of Rs 1 lakh crore in line with the announcement in the interim budget.

- Shivani Thakar

Union Budget Drives Home.'VIKSIT BHARAT' MANTRA

The Budget has enhanced the allocation to the Department of Scientific and Industrial Research (DSIR) from Rs 5746.51 crore in 2023-24 to Rs 6323.41 crore 2024-25 marking an increase of 10.03 per cent, of which Rs 6265.80 crore has been earmarked for Council of Scientific & Industrial Research (CSIR).

The Union Budget 2024-25 is focussed on driving the growth and development of entrepreneurship, employment and skilling, making India a manufacturing hub of the world and boosting primary and secondary healthcare in the country factors by and large being hailed by leaders and experts as keystones on India's path of 'Viksit Bharat' to become one of the world's biggest economy. The Prime Minister asserted "Today's budget has brought new opportunities, new energy, new employment and self-employment opportunities. It has brought better growth and a bright future."

Healthcare/medtech

The government has increased the budget allocation for the healthcare sector by 15 per cent compared to the previous year. This increase aims to improve healthcare infrastructure and services across the country. Three cancer drugs namely Trastuzumab Deruxtecan, Osimertinib and Durvalumab have been fully exempted from custom duty, to make cancer treatment more affordable in the country. The budget has also introduced schemes to enable changes in Basic Customs Duty (BCD) on X-ray tubes & flat panel detectors for use in medical X-ray machines under the Phased Manufacturing Programme. Although the announcements have been welcomed by the healthcare sector, experts opine that customs duty reduction on finished goods is still a pending demand.

Bio Spectrum'den DAHA FAZLA HİKAYE

Bio Spectrum

Bio Spectrum

MAHE teams up with OpenAI to integrate AI to enhance outcomes

Manipal Academy of Higher Education (MAHE), an Institution of Eminence Deemed to be University in Karnataka, has partnered with OpenAI to integrate advanced artificial intelligence (AI) tools across teaching, research, and academic administration.

time to read

1 min

April 2026

Bio Spectrum

Bio Spectrum

Jubilant Bhartia Foundation & McGill University to launch CoE in AI education

The Jubilant Bhartia Foundation in collaboration with McGill University (Canada), has signed a Memorandum of Understanding (MoU) to create the Centre of Excellence (CoE) in artificial intelligence (AI) Education and Research.

time to read

1 min

April 2026

Bio Spectrum

Bio Spectrum

Heeding Auditory Warning Signs

By 2050, nearly 2.5 billion people are projected to have some degree of hearing loss, and more than 700 million might require hearing rehabilitation. That's according to the World Health Organization (WHO).

time to read

2 mins

April 2026

Bio Spectrum

Bio Spectrum

Botanic Healthcare on-boards Narahari Naidu as Group Chief Financial Officer

Secundarabad-based Botanic Healthcare, a globally leading nutraceutical company, has announced the appointment of Narahari Naidu as its Group Chief Financial Officer (CFO).

time to read

1 min

April 2026

Bio Spectrum

Bio Spectrum

Paras Health ropes in Balkishan Sharma as Group CHRO and Business Transformation Officer

Paras Health has announced the appointment of Balkishan Sharma as Group Chief Human Resources Officer (Group CHRO) and Business Transformation Officer.

time to read

1 min

April 2026

Bio Spectrum

Bio Spectrum

Parse Biosciences unveils Evercode Whole Transcriptome V4 with shorter workflow

Parse Biosciences, a Qiagen company, has announced the launch of the new Evercode Whole Transcriptome v4 product line, delivering expanded scalability, higher sensitivity and a simplified workflow for single-cell RNA sequencing. Evercode v4 supports extraordinary scalability of up to five million cells and 384 samples in a single run, enabling researchers

time to read

1 min

April 2026

Bio Spectrum

Bio Spectrum

UK deploys new bone scanners to help prevent fractures

Tens of thousands of patients at risk of osteoporosis and other bone conditions will get faster access to vital bone scans, as 20 new scanners are rolled out across England.

time to read

1 min

April 2026

Bio Spectrum

Bio Spectrum

Cytiva expands Fast Trak process development and validation services facility in India

Cytiva, a Danaher company and a leader in the life sciences industry, has inaugurated an expanded facility for Fast Trak process development (PD) and validation services in Bengaluru.

time to read

1 min

April 2026

Bio Spectrum

Bio Spectrum

ΑΙ TAKES INDIAN PHARMA REINS

The Indian pharmaceutical sector, one of the largest in the world, is undergoing a strategic transformation in the way it operates. As artificial intelligence (AI) gains prominence across the industry, companies are actively adopting Al-driven solutions to enhance efficiency across the entire pharmaceutical ecosystem. Organisations are investing in AI training programmes to keep their workforce future-ready, foster innovation, strengthen supply chains, and transition away from manual record-keeping. In this industry analysis, experts share their perspectives on how AI is shaping the future of the pharma sector.

time to read

10 mins

April 2026

Bio Spectrum

NIH halts arm of clinical trial evaluating potential stroke treatment

The National Institutes of Health (NIH) in the US has stopped an investigational treatment arm of the Comparison of Anti-coagulation and Anti-platelet Therapies for Intracranial Vascular Atherostenosis (CAPTIVA) study, following a regular review by the Data Safety and Monitoring Board (DSMB).

time to read

1 min

April 2026

Listen

Translate

Share

-
+

Change font size